The closing of the Microfluidics sale removes one condition precedent for the Treeline merger. The next catalyst is the stockholder vote on the Treeline transaction, for which the proxy was mailed on October 21, 2026. Monitor for vote results and the closing of the Element Biosystems Mass Cytometry sale.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $0.6108entry
- T+1 · 13d ago +0.85%α −0.80% · $0.6160
- T+5 · 7d ago +8.87%α +9.46% · $0.6650
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Standard BioTools announced the closing of the sale of its Microfluidics business to ARCHIMED, which will operate as Biomark Scientific. The deal was previously announced on October 5, 2026, and this filing confirms completion. No deal value was disclosed in the filing. The sale is part of Standard BioTools' ongoing divestiture process ahead of its pending merger with Treeline Biosciences.
Key Financial Metrics
Key Facts
- Sale of Microfluidics business to ARCHIMED closed on November 3, 2026.
- The business will operate as a standalone entity under the name Biomark Scientific.
- Luke Stewart appointed Chief Commercial Officer of Biomark Scientific.
- ARCHIMED manages 15 billion across its funds.
- The filing also references the pending Treeline Biosciences merger and the Element Biosystems Mass Cytometry sale.
Financial Impact
No deal value disclosed in this filing. Prior cross-filing context noted the Element Biosystems deal for $5.5 million cash and a net cash improvement of $15 million from terminating the prior Multiplex Bio deal. The Microfluidics sale value is not stated.
Risk Factors
- No deal value disclosed for the Microfluidics sale, making it impossible to assess financial impact from this filing alone.
- The filing contains forward-looking statements and solicitation language typical of M&A communications, with no new financial data.
- The pending Treeline merger and Element Biosystems sale remain subject to stockholder approval and closing conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-041711 |
| Document: ef20084814_ex99-1.htm | 0001140361-26-041711 |
| Document: 0001140361-26-041711-index-headers.html | 0001140361-26-041711 |
| Document: 0001140361-26-041711-index.html | 0001140361-26-041711 |
| Document: 0001140361-26-041711.txt | 0001140361-26-041711 |
Track record
23 reports on LAB
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Viewing Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers